Thinking of joining a study?

Register your interest

Become a volunteer?

NCT02356653 | RECRUITING | Leukemia

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
Sponsor:

Children's Hospital of Philadelphia

Information provided by (Responsible Party):

Timothy Olson

Brief Summary:

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.

Condition or disease

Leukemia

Inborn Errors of Metabolism

Bone Marrow Failure Syndromes

Immunodeficiencies

Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome

Intervention/treatment

Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)

Phase

EARLY_PHASE1

Detailed Description:

Only 25-30% of patients who may benefit from HSCT have a matched related donor. There is a higher rate of complications using cells from an unrelated or partially matched related donor. T cells within the donor cells may cause a complication called graft vs. host disease (GVHD). The goal of this study is to use the CliniMACs device to remove the T cells that cause GVHD, called T cell depletion.

Study Type : INTERVENTIONAL
Estimated Enrollment : 100 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Related Donor Peripheral Stem Cells
Actual Study Start Date : 2013-12
Estimated Primary Completion Date : 2027-01
Estimated Study Completion Date : 2030-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: to 30 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Patients who lack a fully HLA matched sibling and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT) but are not deemed suitable candidates per their treating clinical team for current open institutional protocols using ClinMACs device for CD3+/CD19+ depletion.
  • 2. Patients with the following transplantable diseases
    • Non-malignant diseases
      • Metabolic storage diseases correctable by HSCT, Bone marrow failure syndromes, Immunodeficiencies/immune dysregulation syndromes/including HLH, Hemoglobinopathies correctable and requiring HSCT, and Other diseases treated with HSCT/Other non-malignant blood, metabolic, or immune disorders for which HSCT has been recommended
      • Malignant diseases
        • Acute leukemias, Chronic leukemias, Lymphomas, Myelodyplastic syndrome
        • 3. Signed informed consent
        • 4. Lansky or Karnofsky performance ≥60
        • 5. Hematologic and Organ Function per current institutional SOP.
        • 6. Infectious Evaluation as per current institutional SOP.
        • 7. Participants of childbearing potential must have a negative pregnancy test as per institutional SOP
        • 8. In cases that are deemed clinical emergencies (primary or secondary graft failure, severe marrow suppression), the above status criteria will be waived.
        • 9. Patients must have an identified living donor
        • * Donor selection will comply with 21 CFR 1271
        • * Unrelated donor that meets the matching criteria of the NMDP with allele matching at HLA -A, -B, -C, -DRB1, and -DQB1: Unrelated donors may be a 10/10 match, a 9/10 match, or an 8/10 match if one of the mismatches is at DQB1
        • * Related donor suitable for mobilization infectious disease criteria as per SOP, including HIV, HepB, HepC PCR negative.
        • * CHOP BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases. Our donor collection program is FACT accredited.
        • * Unrelated donor identified through the National Marrow Donor Program (NMDP) and fulfills the NMDP criteria for donation. Unrelated donor willing and able to undergo mobilization of peripheral stem cells and apheresis.
        • * The donors selected for this IND will either be unrelated donors identified through the National Marrow Donor Program (NMDP) or related donors. Regarding the unrelated donors; NMDP procedures for determining donor eligibility include donor screening and testing for relevant communicable disease agents and diseases
        Exclusion Criteria
        • 1. Uncontrolled bacterial, viral or fungal infections
        • 2. Fully HLA matched sibling donor
        • 3. Donor unable to donate peripheral stem cells
        • 4. Pregnant participants
Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Location Details

NCT02356653

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Pennsylvania

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104